NeoGenomics (NEO) Set to Announce Quarterly Earnings on Tuesday

NeoGenomics (NASDAQ:NEO - Get Free Report) is set to announce its earnings results before the market opens on Tuesday, November 5th. Analysts expect the company to announce earnings of $0.01 per share for the quarter. Persons that are interested in participating in the company's earnings conference call can do so using this link.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its earnings results on Monday, July 29th. The medical research company reported $0.03 EPS for the quarter. NeoGenomics had a negative return on equity of 2.72% and a negative net margin of 12.50%. The company had revenue of $164.50 million during the quarter, compared to analysts' expectations of $161.82 million. During the same period last year, the firm earned ($0.09) EPS. The business's revenue for the quarter was up 12.0% on a year-over-year basis. On average, analysts expect NeoGenomics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NeoGenomics Trading Up 0.3 %

Shares of NEO traded up $0.04 during trading hours on Tuesday, hitting $13.52. 466,612 shares of the stock traded hands, compared to its average volume of 814,205. The business has a fifty day moving average of $15.02 and a 200-day moving average of $14.71. The firm has a market capitalization of $1.73 billion, a PE ratio of -21.81 and a beta of 1.19. NeoGenomics has a 1-year low of $12.77 and a 1-year high of $21.22. The company has a current ratio of 2.01, a quick ratio of 1.93 and a debt-to-equity ratio of 0.37.

Analyst Ratings Changes

A number of analysts have commented on the stock. Benchmark reaffirmed a "buy" rating and set a $18.00 target price on shares of NeoGenomics in a report on Tuesday, September 24th. Needham & Company LLC reiterated a "buy" rating and issued a $19.00 price objective on shares of NeoGenomics in a report on Wednesday, September 25th. Finally, Stephens reissued an "overweight" rating and issued a $19.00 target price on shares of NeoGenomics in a research note on Tuesday, July 30th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $19.89.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.